Non-Muscle Invasive Bladder Cancer Global Market Report 2025

Non-Muscle Invasive Bladder Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-muscle invasive bladder cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.
Description:

Where is the largest and fastest growing market for non-muscle invasive bladder cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-muscle invasive bladder cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope

Markets Covered:1) By Stage: Carcinoma In Situ (CIS); T1 Stage; Ta Stage

2) By Treatment: Immunotherapy; Chemotherapy; Surgery; Intravesical Therapy; Others Treatments

3) By Tumor: Low-Grade Tumours; High-Grade Tumours

4) By End-User: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy

Subsegments:

1) By Carcinoma In Situ (CIS): High-Grade CIS; Low-Grade CIS

2) By T1 Stage: T1a Stage (Superficial Tumors); T1b Stage (Invasive Into Lamina Propria)

3) By Ta Stage: Low-Grade Ta Stage; High-Grade Ta Stage

Companies Mentioned:Johnson & Johnson; Janssen Research & Development LLC; Merck & Co. Inc.; AstraZeneca plc; Moderna Inc.

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery format: PDF, Word and Excel Data Dashboard.

Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order.


1. Executive Summary
2. Non-Muscle Invasive Bladder Cancer Market Characteristics
3. Non-Muscle Invasive Bladder Cancer Market Trends And Strategies
4. Non-Muscle Invasive Bladder Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Non-Muscle Invasive Bladder Cancer Growth Analysis And Strategic Analysis Framework
5.1. Global Non-Muscle Invasive Bladder Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Non-Muscle Invasive Bladder Cancer Market Growth Rate Analysis
5.4. Global Non-Muscle Invasive Bladder Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Non-Muscle Invasive Bladder Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Non-Muscle Invasive Bladder Cancer Total Addressable Market (TAM)
6. Non-Muscle Invasive Bladder Cancer Market Segmentation
6.1. Global Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Carcinoma In Situ (CIS)
T1 Stage
Ta Stage
6.2. Global Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immunotherapy
Chemotherapy
Surgery
Intravesical Therapy
Other Treatments
6.3. Global Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Low-Grade Tumours
High-Grade Tumours
6.4. Global Non-Muscle Invasive Bladder Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
6.5. Global Non-Muscle Invasive Bladder Cancer Market, Sub-Segmentation Of Carcinoma In Situ (CIS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
High-Grade CIS
Low-Grade CIS
6.6. Global Non-Muscle Invasive Bladder Cancer Market, Sub-Segmentation Of T1 Stage, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
T1a Stage (Superficial Tumors)
T1b Stage (Invasive Into Lamina Propria)
6.7. Global Non-Muscle Invasive Bladder Cancer Market, Sub-Segmentation Of Ta Stage, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Low-Grade Ta Stage
High-Grade Ta Stage
7. Non-Muscle Invasive Bladder Cancer Market Regional And Country Analysis
7.1. Global Non-Muscle Invasive Bladder Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Non-Muscle Invasive Bladder Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Non-Muscle Invasive Bladder Cancer Market
8.1. Asia-Pacific Non-Muscle Invasive Bladder Cancer Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Non-Muscle Invasive Bladder Cancer Market
9.1. China Non-Muscle Invasive Bladder Cancer Market Overview
9.2. China Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Non-Muscle Invasive Bladder Cancer Market
10.1. India Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Non-Muscle Invasive Bladder Cancer Market
11.1. Japan Non-Muscle Invasive Bladder Cancer Market Overview
11.2. Japan Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Non-Muscle Invasive Bladder Cancer Market
12.1. Australia Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Non-Muscle Invasive Bladder Cancer Market
13.1. Indonesia Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Non-Muscle Invasive Bladder Cancer Market
14.1. South Korea Non-Muscle Invasive Bladder Cancer Market Overview
14.2. South Korea Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Non-Muscle Invasive Bladder Cancer Market
15.1. Western Europe Non-Muscle Invasive Bladder Cancer Market Overview
15.2. Western Europe Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Non-Muscle Invasive Bladder Cancer Market
16.1. UK Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Non-Muscle Invasive Bladder Cancer Market
17.1. Germany Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Non-Muscle Invasive Bladder Cancer Market
18.1. France Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Non-Muscle Invasive Bladder Cancer Market
19.1. Italy Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Non-Muscle Invasive Bladder Cancer Market
20.1. Spain Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Non-Muscle Invasive Bladder Cancer Market
21.1. Eastern Europe Non-Muscle Invasive Bladder Cancer Market Overview
21.2. Eastern Europe Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Non-Muscle Invasive Bladder Cancer Market
22.1. Russia Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Non-Muscle Invasive Bladder Cancer Market
23.1. North America Non-Muscle Invasive Bladder Cancer Market Overview
23.2. North America Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Non-Muscle Invasive Bladder Cancer Market
24.1. USA Non-Muscle Invasive Bladder Cancer Market Overview
24.2. USA Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Non-Muscle Invasive Bladder Cancer Market
25.1. Canada Non-Muscle Invasive Bladder Cancer Market Overview
25.2. Canada Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Non-Muscle Invasive Bladder Cancer Market
26.1. South America Non-Muscle Invasive Bladder Cancer Market Overview
26.2. South America Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Non-Muscle Invasive Bladder Cancer Market
27.1. Brazil Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Non-Muscle Invasive Bladder Cancer Market
28.1. Middle East Non-Muscle Invasive Bladder Cancer Market Overview
28.2. Middle East Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Non-Muscle Invasive Bladder Cancer Market
29.1. Africa Non-Muscle Invasive Bladder Cancer Market Overview
29.2. Africa Non-Muscle Invasive Bladder Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Non-Muscle Invasive Bladder Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Non-Muscle Invasive Bladder Cancer Market, Segmentation By Tumor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Non-Muscle Invasive Bladder Cancer Market Competitive Landscape And Company Profiles
30.1. Non-Muscle Invasive Bladder Cancer Market Competitive Landscape
30.2. Non-Muscle Invasive Bladder Cancer Market Company Profiles
30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Janssen Research & Development LLC Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis
31. Non-Muscle Invasive Bladder Cancer Market Other Major And Innovative Companies
31.1. Astellas Pharma US Inc.
31.2. Ferring Pharmaceuticals
31.3. EMD Serono Inc.
31.4. Fidia Farmaceutici SpA
31.5. Genentech Inc.
31.6. Aura Biosciences Inc.
31.7. UroGen Pharma Ltd.
31.8. Asieris Pharmaceuticals
31.9. Protara Therapeutics Inc.
31.10. Hamlet Pharma AB
31.11. Istari Oncology Inc.
31.12. Heat Biologics Inc.
31.13. Telormedix SA
31.14. Viventia Bio Inc.
31.15. Theralase Technologies Inc.
32. Global Non-Muscle Invasive Bladder Cancer Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Non-Muscle Invasive Bladder Cancer Market
34. Recent Developments In The Non-Muscle Invasive Bladder Cancer Market
35. Non-Muscle Invasive Bladder Cancer Market High Potential Countries, Segments and Strategies
35.1 Non-Muscle Invasive Bladder Cancer Market In 2029 - Countries Offering Most New Opportunities
35.2 Non-Muscle Invasive Bladder Cancer Market In 2029 - Segments Offering Most New Opportunities
35.3 Non-Muscle Invasive Bladder Cancer Market In 2029 - Growth Strategies
35.3.1 Market Trend Based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings